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An empirical tool for estimating the share of
unmet need due to healthcare inefficiencies,
suboptimal access, and lack of effective
technologies
Devin Incerti1* , John Browne2, Caroline Huber1, Christine L. Baker3, Geoff Makinson3, Amir Goren4,
Richard Willke5 and Warren Stevens6
Abstract
Background: Although there has been growing attention to the measurement of unmet need, which is the overall
epidemiological burden of disease, current measures ignore the burden that could be eliminated from technological
advances or more effective use of current technologies.
Methods: We developed a conceptual framework and empirical tool that separates unmet need from met need and
subcategorizes the causes of unmet need into suboptimal access to and ineffective use of current technologies and
lack of current technologies. Statistical models were used to model the relationship between health-related quality of
life (HR-QOL) and treatment utilization using data from the National Health and Wellness Survey (NHWS). Predicted HR-
QOL was combined with prevalence data from the Global Burden of Disease Study (GBD) to estimate met need and
the causes of unmet need due to morbidity in the US and EU5 for five diseases: rheumatoid arthritis, breast cancer,
Parkinson’s disease, hepatitis C, and chronic obstructive pulmonary disease (COPD).
Results: HR-QOL was positively correlated with adherence to medication and patient-perceived quality and negatively
correlated with financial barriers. Met need was substantial across all disease and regions, although significant unmet
need remains. While the majority of unmet need was driven by lack of technologies rather than ineffective use of
current technologies, there was considerable variation across diseases and regions. Overall unmet need was largest for
COPD, which had the highest prevalence of all diseases in this study.
Conclusion: We developed a methodology that can inform decisions about which diseases to invest in and
whether those investments should focus on improving access to currently available technologies or inventing
new technologies.
Keywords: Unmet need, Quality of life, Healthcare inefficiency, Access to healthcare, Health economics, Inequality
Background
With the rapid development of innovative health technolo-
gies and therapies, and constraints on public resources,
there is a growing interest in identifying conditions with
the most significant disease burden and needs to better al-
locate resources and improve patient health. One approach
to identifying such conditions uses the measurement of
unmet need, which is the overall epidemiological burden of
disease [1]. Unmet need for healthcare can refer to the need
for new technologies, the need for improved access to
current technologies, or the imperfect use of current tech-
nologies. The overall magnitude of unmet need is driven by
each of these subcategories, as well as the underlying intrin-
sic burden of the condition in question. Therefore, quanti-
fying these subcategories of unmet need is critical to
informing the allocation of scarce healthcare resources and
prioritizing future research and development (R&D) invest-
ments by both the public and private sectors [2, 3].
* Correspondence: Devin.Incerti@PrecisionHealthEconomics.com
1Precision Health Economics, 11100 Santa Monica Blvd #500, Los Angeles, CA
90025, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Incerti et al. BMC Health Services Research          (2019) 19:113 
https://doi.org/10.1186/s12913-019-3914-7
Despite the interest in measuring unmet need, current
measures are rudimentary and receive little attention in
the health economics literature and policy discussions. A
number of studies have described conceptual models of
unmet need [1, 4, 5]. In these studies, measures of un-
met need generally describe the gap between disease
burden and the degree to which that burden can cur-
rently be overcome, but these measures ignore the burden
that could be eliminated through technological advances
[6–9]. Many epidemiological studies have attempted to de-
fine and estimate unmet need within specific diseases or
therapeutic approaches [4, 10–15]. However, few studies
have attempted to measure unmet need across multiple dis-
eases while using uniform methodologies and outcome
measures [10, 16, 17].
A further limitation of current measures of unmet
need is the use of the disability-adjusted life year
(DALY), which is the most popular measure of overall
disease burden. DALYs are useful for comparing the ag-
gregate burden across conditions and across countries.
They are limited, however, when valuing the extent to
which new technologies can reduce unmet need, be-
cause they do not express need in the same currency as
cost-effectiveness, which currently is the quality-ad-
justed life year (QALY) [10]. Furthermore, DALYs usu-
ally are not measured at the individual patient level,
which is required to link determinants of unmet need,
such as insurance coverage, with treatment utilization.
In light of these limitations, and a need to better
understand the needs of patients, we developed a con-
ceptual framework and empirical tool that not only al-
lows unmet need to be measured using a single outcome
measure shared across all diseases, but also separates
unmet from met need and subcategorizes the causes of
unmet need.
By standardizing unmet need across diseases and
stratifying unmet need by category, iterations of this
framework and tool can be useful for decision-makers
as they make resource allocation decisions. For ex-
ample, they could be used by health technology manu-
facturers to prioritize R&D investments or policy-
makers to inform disease areas that require stronger
health system infrastructure. Through this manuscript,
we aim to clearly articulate our approach to inform
additional research in measuring unmet need.
Methods
Figure 1 illustrates our conceptual approach to disaggre-
gating unmet need for whole populations with a specific
condition. The figure maps health against age, and as-
sumes that disease burden, ceteris paribus, increases as
people age, regardless of the source of unmet need. It
also assumes that, beyond a certain age, comorbidities
prevent perfect health from being achieved, even if a
specific condition has been eliminated through techno-
logical advances.
Our approach facilitates discrimination between sub-
populations with different hypothetical levels of need.
These are, in order of severity: (1) patients with untreated
disease (disease burden, untreated); (2) patients with sub-
optimal access to or ineffective use of state-of-the-art
technologies (current disease burden); (3) patients with ac-
cess to and use of state-of-the-art technologies (achievable
met need); and (4) patients receiving new technologies
that eliminate the condition in question (no disease bur-
den). An achieved state of (2) vs. (1) represents current
Fig. 1 Subcategories of unmet need. Notes: This figure represents the conceptual approach to disaggregating unmet need for whole populations
with a specific condition. The x-axis represents age, and the y-axis represents the disease burden of a specific condition. The approach assumes
that, ceteris paribus, disease burden increases with age
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met need, or the extent that current technologies have re-
duced disease burden. The gap between (4) and (2) repre-
sents remaining unmet need, which is decomposed into
unmet need due to ineffective use of current technologies
(gap between (3) and (2)) and lack of technologies (gap
between (4) and (3)), respectively.
In principle, categories of disease burden for a given
disease can be estimated using a modified version of the
DALY,
DALY ða; g; cÞ ¼ YLLða; g; cÞ þ YLDða; g; cÞ ð1Þ
where, for a given age group a, gender g, and category c,
YLL is years of life lost due to premature mortality and
YLD is years lost due to disability. To estimate this quan-
tity empirically, data on treatment access and use must be
combined with data on morbidity and mortality. For re-
sults to be generalizable, these data must be available
across a number of diseases and countries. Morbidity in
the DALY framework is estimated using disability weights
that are derived from a population survey; our framework
replaces this with a disutility weight, equivalent to the loss
of utility arising from unmet need. While we treat mortal-
ity in the same way as in the DALY framework, it is also
possible to assume equivalence across conditions and use
morbidity data alone when comparing chronic conditions
with negligible survival impact.
Data sources
Quantifying unmet need first requires an assessment
of current disease prevalence and mortality and the
level of health achievable in the various benchmark
scenarios described above. The most comprehensive
global source for the prevalence and mortality data re-
quired is the Global Burden of Disease Study (GBD),
which provides estimates of the incidence, prevalence,
and mortality of over 310 diseases and sequelae for
each country, by year [18].
Second, it also requires patient-level measures of health
status that can be analyzed with the main causes of unmet
need. That is, the extent to which better use and access to
healthcare can reduce the burden of disease must be mea-
sured, in addition to the impact of disease. Routinely-col-
lected surveys such as the Medical Expenditure Panel
Survey (MEPS) [19], the Health and Retirement Study
(HRS) [20], and the National Health and Wellness Survey
(NHWS) [21] provide these data. In this study, we selected
the NHWS because it uses the same survey tools in mul-
tiple countries, which facilitates comparison across terri-
tories and health systems. Although a limitation of the
NHWS is that it does not contain data on mortality, we
determined that its multi-country coverage and rich
quality-of-life data provided significant advantages over
other potential data sources.
We selected five epidemiologically-diverse conditions
that significantly impact morbidity, which allowed us to
assess the usefulness of our empirical tool: rheumatoid
arthritis (RA), breast cancer, Parkinson’s disease, hepa-
titis C, and chronic obstructive pulmonary disease
(COPD). For each disease, we calculated years of life lost
to disutility (YLD),
YLDða; g; cÞ ¼ DW ða; g; cÞ  pða; g; cÞ ð2Þ
where DW is a disutility weight and p is the prevalence
of disease. The key difference between this measure and
the GBD’s “years of life lost to disability” weight is the
replacement of the disability weight with the health-
related quality of life (HR-QOL)-based disutility weight.
Variables
The YLD measure was estimated separately for the United
States (US) and five European countries (United Kingdom,
Germany, France, Italy, and Spain, hereafter referred to as
the EU5). We obtained data on prevalence by age, gender,
and country from the GBD Results Tool [22].
The disutility weights were estimated using 2013 data
from the NHWS. 75,000 individuals were surveyed in
the US, and 62,000 individuals were surveyed in the
EU5. The survey uses recent census data in each geo-
graphical region to design a sampling plan so that the
survey is representative of the adult population. The sur-
vey is self-reported, cross-sectional, and online-based,
but uses off-line recruitment techniques to ensure that
the elderly population is well-represented.
Surveyed individuals completed the Short-Form 36-
item (version 2; SF-36v2) health survey, and responses
were converted into Short-Form Six-Dimension (SF-6D)
utility scores using the algorithm described in Brazier et
al. [23]. The utility scores range from scores below 0
representing health states worse than death to a max-
imum score of 1 equivalent to perfect health. Disutility
was calculated as “1 – utility.” Additional details are pro-
vided in the Additional file 1.
In the NHWS, medical conditions are self-reported
and based on responses to the survey questionnaire. In-
dicator variables were used to indicate whether a re-
spondent had one of the five conditions of interest. We
also calculated the number of comorbidities for each re-
spondent, which were classified into four groups: zero
comorbidities, one comorbidity, two commodities, or at
least three comorbidities.
We measured the impact of poor access to and utilization
of care by comparing utility with observed treatments to
expected utility given currently available technologies.
Three types of variables (four in total) were used to meas-
ure access to and use of technologies. First, the Morisky
Medication Adherence Scale, 8-item (©MMAS-8) was used
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to measure the degree to which patients are adhering to
medications. Respondents were coded according to
whether they had high adherence (1) or low or medium ad-
herence (0). Second, two variables were used as proxies for
access to care. The first variable assessed whether respon-
dents reported that costs prevented them from taking med-
ications (1 = yes, 0 = no), and the second assessed whether
respondents used a cost-cutting strategy for their medica-
tions (1 = yes, 0 = no). Third, we used a variable asking
whether respondents feel their doctors are attentive to their
needs and concerns (1 = yes, 0 = no), as a proxy for the
quality of received care.
Modeling disutility weights
We estimated disutility weights for different categories
of YLD by modeling the relationship between treatment
utilization and HR-QOL-based utility. Specifically, we
used linear regression to model utility (i.e., 1 – disutility)
for each survey respondent in the NHWS as a function
of four types of variables: (1) indicator variables for the
five conditions of interest, (2) measures of comorbidity,
(3) age and gender, and (4) sources of unmet need. The
coefficients on the medical condition variables are mea-
sures of the disutilities of those conditions, after control-
ling for age, gender, and comorbidities. The sources of
unmet need analyzed were financial barriers to care,
treatment quality, and treatment adherence. These vari-
ables were interacted with the indicator variables for
each of the five conditions, which allowed the effect of
access to and use of available technologies to vary across
conditions. Mathematical details of the regression model
are included in the Additional file 1.
Using the statistical model to predict utility
The statistical model was used to predict utility for cat-
egories of YLD. Predictions were made separately for
each respondent in the data who reported having one
of the five conditions. Utility scores by category are
mean predictions by age and gender across respon-
dents. Mean utility was calculated separately for each of
the five conditions.
We first estimated current disease burden by predicting
utility, given variables for each respondent were equal to
their observed values. Counterfactual scenarios were used
to estimate the remaining three subcategories. In the first
two counterfactual scenarios, we used the variables meas-
uring access to and use of care to examine the extent to
which current technology reduces unmet need. We esti-
mated the disease burden untreated by assuming that each
respondent switched from observed care to no care. That
is, we predicted utility for each respondent when the
values of each of the four access and utilization variables
were set to their “worst” values (i.e., low adherence, costs
prevent medication use, used cost-cutting strategy, doctor
is not attentive to needs and concerns). Conversely, the
achievable disease burden category was estimated by as-
suming that each respondent switched from observed care
to perfect care by setting the access and utilization vari-
ables to their “optimal” values. In the remaining counter-
factual scenario, we estimated the no disease burden
category by assuming that each respondent no longer had
the disease in question and that respondents received op-
timal treatment. The increase in utility from the current
met need category to the no disease burden category is
consequently equal to the estimated disutility of the dis-
ease for patients using current treatments optimally.
Estimating years of quality-adjusted life lost to disutility
(YLD)
YLD by age, gender, and unmet need category were eval-
uated for each of the five diseases using Eq. 2 by multi-
plying disutility weights for a given category by the
prevalence of disease in that category. Total YLD was
calculated by summing across age and gender.
Results
Table 1 provides information related to the impact of
the variables used in the statistical model on utility and
highlights the frequency of particular demographic char-
acteristics, comorbidities, medical conditions, and poor
access and use of care. The results show that the access
and utilization variables have the expected association
with utility. Utility was lower for respondents who re-
ported that costs created barriers to medication use and
higher for respondents with better adherence to their
medications or who believed that their physicians were
attentive to their needs and concerns. The relationship
between disease severity and utility is also of note. Re-
spondents who did not use medications had lower utility
scores, suggesting that not using medication is a proxy
for disease severity. Moreover, utility was negatively cor-
related with the number of comorbidities.
The impact of the access and utilization variables on
utility is shown in Fig. 2. The figure reports regression
coefficients from the full statistical model, which con-
trols for age, gender, and disease severity. We would
have expected the coefficients on the two cost-related
variables to be negative, the coefficient on the adherence
variables to be positive, and the coefficient on the phys-
ician attentiveness variable to be positive. This was gen-
erally observed, with a few exceptions, such as the
coefficient on high adherence for respondents with RA
in the EU5. Estimates of all regression coefficients in the
model are reported in the Additional file 1: Table S1.
Figure 3 examines the impact of the five medical condi-
tions on utility. The estimates are measures of the disutil-
ity of each condition given current access to and use of
technology, since they were calculated with all variables in
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Table 1 Utility scores of 2013 NHWS survey respondents by demographics, disease severity, access and utilization
EU5 US
N % Mean utility N % Mean utility
Age group
18–34 16,964 27% 0.73 19,421 26% 0.73
35–54 24,005 39% 0.73 26,293 35% 0.75
55–74 19,266 31% 0.72 25,821 34% 0.76
75+ 1765 3% 0.69 3465 5% 0.75
Gender
Female 33,305 54% 0.71 38,711 52% 0.74
Male 28,695 46% 0.74 36,289 48% 0.75
Number of comorbidities
0 26,067 42% 0.77 26,363 35% 0.79
1 13,836 22% 0.73 14,800 20% 0.76
2 9056 15% 0.70 10,915 15% 0.75
3 or more 13,041 21% 0.64 22,922 31% 0.69
Cost prevented medication use
No 54,733 88% 0.73 58,012 77% 0.77
Yes 7267 12% 0.65 16,988 23% 0.68
Used a cost cutting strategy for medications
No 47,138 76% 0.74 44,343 59% 0.78
Yes 14,862 24% 0.66 30,657 41% 0.71
Doctor was attentive to needs and concerns
No 8565 14% 0.70 6717 9% 0.71
Yes 53,435 86% 0.73 68,283 91% 0.75
Adherence
Breast cancer
Not using medications 487 64% 0.67 740 72% 0.73
Low/medium adherence 166 22% 0.61 148 14% 0.67
High adherence 104 14% 0.67 145 14% 0.78
COPD
Not using medications 291 30% 0.64 399 20% 0.65
Low/medium adherence 423 43% 0.58 892 45% 0.60
High adherence 268 27% 0.62 712 36% 0.66
Hepatitis C
Not using medications 356 85% 0.65 598 91% 0.66
Low/medium adherence 50 12% 0.58 62 9% 0.56
High adherence 13 3% 0.62 15 2% 0.68
Parkinson’s
Not using medications 36 33% 0.63 35 24% 0.63
Low/medium adherence 49 45% 0.57 71 48% 0.58
High adherence 25 23% 0.63 42 28% 0.71
Rheumatoid arthritis
Not using medications 215 31% 0.63 251 21% 0.64
Low/medium adherence 313 45% 0.58 581 48% 0.60
High adherence 165 24% 0.57 369 31% 0.64
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the statistical model set to their observed values. The coef-
ficient on each condition was negative in both the EU5
and the US, implying that the conditions decreased utility,
ceteris paribus. Overall, disutilities ranged from around −
0.03 to − 0.13 and were similar in both geographic regions.
The coefficients were estimated precisely, as the 95% con-
fidence intervals did not cross zero. The disutility esti-
mates can be interpreted as the amount that patient utility
would increase if a condition were completely eliminated.
We predicted utility using our statistical model by
subcategory of met and unmet need in Fig. 4. For each
of the diseases, the figure decomposes total need as
measured by utility (i.e., ignoring prevalence) in the
EU5 and US into the proportion that is currently being
met, could be met given current technologies, and
could be met given future technologies. In most cases,
current technologies increased utility considerably, al-
though significant unmet need remains. While ensuring
better access to and use of available technologies could
reduce some of the unmet need gap, this gap, with the
exception of breast cancer in the US, was driven mostly
by lack of technologies.
Figure 5 displays estimates of YLD, which combines
the utility data shown in Fig. 4 with prevalence data
from the GBD. The figure contains the same three sub-
categories of met and unmet need as in Fig. 4, but adds
a fourth category, which is the extent to which unmet
need would still exist because of comorbidities, even if
the condition in question was completely eliminated. Al-
though the extent of unmet need caused by comorbidi-
ties is substantial, future innovations and more effective
use of current technologies could substantially reduce
disease burden. The disease burden for COPD is worth
highlighting given its large magnitude; for example, our
results imply that more efficient use of current technolo-
gies in the US would reduce YLD by 451,447 and that fu-
ture technologies could reduce YLD by another 1,446,507.
Discussion
Our study presents a new conceptual framework for un-
derstanding unmet need and demonstrates how it can be
applied empirically to compare the magnitude of unmet
need across conditions and countries. The proposed ap-
proach presents considerable technical challenges, largely
Fig. 2 Association between access, utilization variables and utility. Notes: Dependent variable is each respondent’s utility score. Error bars are 95%
confidence intervals
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Fig. 3 Adjusted disutility of disease. Notes: Adjusted disutility in the figure is predicted disutility from the model averaged across all individuals in the
NHWS, with the access and utilization variables set to their observed values. Error bars are 95% confidence intervals. Standard errors were calculated by
using the simulation-based method described in Mandel et al. [30] In particular, coefficients from the regression model were simulated 1000 times
using an asymptotic normal distribution. For each of the 1000 simulations, disutility was predicted for all survey respondents with a given medical
condition. Mean disutility was then calculated across individuals for each draw and the mean, 2.5% quartile, and 97.5% quartile of mean disutility were
used to generate the point estimates and 95% confidence intervals in the plot
Fig. 4 Predicted utility by categories of met and unmet need. Notes: This figure shows predicted utility by subcategory of met and unmet need
by disease and geographic area. Total need is measured by utility and is broken into current met need, unmet need from ineffective use of
technologies and unmet need from a lack of technologies
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due to data requirements, but these can be overcome using
comprehensive international datasets such as the NHWS.
The results presented have good face validity. For example,
it is reassuring that the amount of unmet need associated
with financial barriers to care was higher in the US, which
has multiple public and private payers, than in European
countries with universal health coverage.
More comprehensive research efforts in this area
could demonstrate where societies and private compan-
ies would reap the greatest benefits from improving ac-
cess to currently available drugs and technologies,
improving the application of such therapies, and invest-
ing in the development of new therapies. While such
efforts could ultimately help prioritize resource alloca-
tion by disease and type of intervention, efforts are still
needed to overcome some of the limitations of this
study. Below, we outline these limitations and highlight
areas where future research would be most beneficial.
Data limitations
As with many modeling efforts, many of the limitations of
our work concern data scope and quality. For instance,
since the NHWS is a self-reported survey, the manner of
recruitment and survey administration may represent a
form of selection bias, and the responses may be subject to
recall bias or misinterpretation of the questions. Further-
more, while the NHWS uses the same survey in multiple
geographical locations, it is not undertaken everywhere.
There are also sample size limitations, as some rare condi-
tions in smaller countries do not provide enough data to
effectively generate usable results. We chose two large
regions – the US and Europe – because they represent a
large proportion of global medical technology utilization.
We concentrated on a selection of non-communicable dis-
eases that impose a large morbidity burden in order to sim-
plify the analyses and demonstrate the value of using
HR-QOL disutility as our main outcome. It is inevitable
that including mortality in the analyses would have changed
the relative size of unmet need for different conditions, for
example, increasing the relative size of unmet need in
breast cancer.
The NHWS is cross-sectional, which limits the causal
interpretation of our findings. Specifically, we assumed
that the access, utilization, and disease variables have a
causal effect on utility after controlling for age, gender,
and comorbidities. To the extent that this is not the
case, our counterfactual scenarios may be biased. New
longitudinal datasets with multiple observations per in-
dividual would be welcome and allow future re-
searchers to leverage time-series variation to estimate
model parameters.
Our model focused on three drivers of achievable unmet
need: financial barriers, patient-perceived quality, and ad-
herence. There are other drivers that may be relevant,
which we could not address with the NHWS data. These
include geographical access barriers, regulatory barriers
such as unapproved technologies, and medical errors un-
known to the patient. Although these factors will likely be
correlated with the variables we currently measure, the
likely effect of including these in any future models will be
to increase the level of achievable unmet need and shrink
the level of unmet need caused by lack of technology.
Fig. 5 Years lost to disutility by categories of met and unmet need. Notes: This figure displays estimates of YLD, which combines the utility data
(as shown in Fig. 4) with prevalence data from the GBD for each disease and geographic area. Utility is broken into current met need, unmet
need from ineffective use of technologies, unmet need from a lack of technologies, and extent to which unmet need would still exist because of
comorbidities, even if the condition in question was completely eliminated
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Finally, our study measured the drivers of achievable
unmet need directly from patients. This has some limita-
tions because patients are unaware of many aspects of
unmet need, particularly around the quality of their
treatment. There is also the danger of ‘common method
variance’ where associations between patient-reported
health status and the sources of unmet need are driven
by underlying response tendencies.
Model limitations
It should be noted that this model does not put a value on
unmet need. In a standard economics framework, the ag-
gregate willingness to pay (WTP) of individuals for a tech-
nology that eliminates a given disease reflects the value of
that technology to society. In recent years, economics has
made considerable progress in incorporating societal dis-
tributive concerns [24, 25]. To the extent that the meas-
urement of unmet need is important, insofar as it helps
society prioritize healthcare resources, measuring societal
value is an approach to measuring unmet need grounded
in economic theory. Economists have long argued that the
value individuals place on the alleviation of disease relies
heavily on context, including the relative severity of dis-
ease, patient age and gender, and proximity to end of life,
among other factors [26, 27]. The value that society places
on the alleviation of disease can be combined with the
QALY estimates of disease burden from our model to pro-
vide a richer measure of unmet need, but this is outside
the scope of this current model.
Further, the current model cannot be used to
prioritize different types of investments. For instance,
our results do not allow decision-makers to determine
whether they should invest in policies that improve ac-
cess to care or that increase adherence. Likewise, our
current model does not inform decisions about whether
to invest in more effective use of current technologies or
disease prevention. The latter may particularly relevant for
diseases like COPD that are often caused by risky health
behaviors such as smoking. Future research that considers
both new drivers of achievable met need and that quanti-
fies their relative importance would be valuable.
Strengths and applications
The most insightful and interesting results from our
model relate to differences between the US and Eur-
ope in terms of the underlying levels of disutility expe-
rienced across diseases and also the degree to which
different causes of unmet need proliferate across terri-
tories and diseases.
A surprising finding from our model was that it pre-
dicted that baseline utility levels across all diseases if treat-
ment was optimally effective – i.e. all disease burden of
the disease in question was addressed – were higher in
the US than in the EU5, as can be seen in Fig. 4. There are
a number of possible explanations for these differences in-
cluding that there is less comorbidity in the US population
(which appears untrue given the results presented in
Table 1) or that there are cultural or regional differences
in how people value or experience HR-QOL in the two
geographic regions (which seems likely given that utility
scores are higher in the US even conditional on the num-
ber of comorbidities). Estimates of met need for four dis-
eases: COPD, Parkinson’s, RA and hepatitis C were all
very similar when comparing the EU5 and US. The only
met need scale that differed significantly was in breast
cancer, where numerous studies have highlighted that
both earlier detection and overtreatment is common in
the US compared with the EU5 [28, 29]. Unsurprisingly,
the size of ‘unmet need due to lack of access to tech-
nologies’ was larger in the US than in the EU5 coun-
tries, as all five of these countries have a healthcare
system based around universal access to healthcare,
whereas the US system, at least in the years studied,
has a significant proportion of its population suffering
from a lack of access to healthcare.
In addition, Fig. 5 highlights the overall scale of the differ-
ent diseases in each territory. In both panels, COPD dwarfs
the other diseases. Clearly this was a function of the preva-
lence of COPD more widely, but it is clear that COPD
should be a priority for the development of new health
technologies. Interestingly, the disease with the second
highest unmet need from lack of technologies was hepatitis
C, but this is due to the fact that the year of data collected
was prior to the introduction of a series of highly-effica-
cious antiretrovirals. Similarly, perhaps reflecting the timing
of the study, the bulk of unmet need in RA was lack of ac-
cess to current technologies in the US, whereas it was a
lack of effective technologies in the EU. This could be at-
tributable to the wider range of RA drugs available in the
US in 2013 than in almost all of the EU5 countries.
These results only highlight a small set of select dis-
eases, but they do have potential to draw considerable
insight into the often-neglected aspect of the informa-
tional requirements of resource allocation and priority
setting in healthcare, not just for present healthcare pol-
icy, but also for directing investment into future tech-
nologies in different disease areas, in terms of potential
return on investment.
Conclusion
An accurate assessment of the health needs of a popula-
tion is critical to allocating scarce healthcare resources
across diseases. Unmet need has emerged as a concept
to define how the health of a population differs from
what is achievable. Although an intuitively obvious need,
a conceptual framework for both defining and measuring
unmet need has remained lacking. Unmet need may take
a short-term perspective that reflects the gap between
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current disease burden and disease burden that would
exist if all individuals had access to available treatment,
or it may take a long-term perspective that reflects the
gap between current disease burden and normal aging.
Such a perspective is important to identifying areas
where research and development into new technologies
may be needed most.
Our approach attempts to quantify these categories in
two different regions across a select set of diseases in
terms of HR-QOL. While the approach is not without
limitations, and there is no guarantee that additional in-
vestments will lead to effective new treatments, we be-
lieve our framework and model can inform health
systems in terms of directing investment activity be-
tween improving access to medicines or increasing in-
vestment in research and development across and within
disease areas. Future research should refine our method-
ology, expand our analyses to other disease areas, and
consider the use and collection of new data.
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